Previous close | 2.7000 |
Open | 2.7000 |
Bid | 2.2000 |
Ask | 2.6500 |
Strike | 130.00 |
Expiry date | 2024-10-18 |
Day's range | 2.7000 - 2.7000 |
Contract range | N/A |
Volume | |
Open interest | 11 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.